cloudfront
  • info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) | +1-214-736-7666 (US) | +1-740-994-0111 (US)
  • Sign In
  • Register

Report Detail



Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Stakeholders
2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Instruments
2.1.1.1. Secondary Instrument
2.1.1.2. Primary Instrument
2.1.2. Research Approaches
2.1.2.1. Bottom-up Approach
2.1.2.2. Top-down Approach
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.1.5. Vendor Inclusion Criteria
2.2. Forecasting Methodology
2.2.1. Methodology for Market Estimation & Forecasting
2.2.2. Significance and Importance of the Market Estimation & Forecasting
3. Executive Summary
3.1. Market Snapshot
3.2. Market Dynamics
3.3. Competitive Analysis
4. Premium Insight
4.1. Market Connectivity
4.2. Market Data Feed
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Changing lifestyle of people and irregular dietary habits
4.3.1.2. Strong product pipeline of antidiabetics
4.3.1.3. Globally rising prevalence of diabetes and increasing obesity among people
4.3.1.4. Increasing consumer awareness level and improved technology
4.3.2. Restraints
4.3.2.1. Prohibitive cost of Insulin
4.3.3. Opportunities
4.3.3.1. Advancement in the healthcare and pharmaceutical sectors
4.3.3.2. Ongoing research and development
4.3.3.3. Governments and private companies to work together for the supply of inexpensive drugs
4.3.4. Challenges
4.3.4.1. Wide availability of antidiabetics drugs
4.4. Porter’s Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Threat of Substitutes
4.4.3. Bargaining Power of Customers
4.4.4. Bargaining Power of Suppliers
4.4.5. Industry Rivalry
5. Global Antidiabetic Drug Market, by Disease
5.1. Diabetes Mellitus Type 1
5.1.1. Overview
5.1.2. Market Sizing & Forecasting
5.2. Diabetes Mellitus Type 2
5.2.1. Overview
5.2.2. Market Sizing & Forecasting
6. Global Antidiabetic Drug Market, by Patient
6.1. Adult
6.1.1. Overview
6.1.2. Market Sizing & Forecasting
6.2. Geriatric
6.2.1. Overview
6.2.2. Market Sizing & Forecasting
6.3. Pediatric
6.3.1. Overview
6.3.2. Market Sizing & Forecasting
7. Global Antidiabetic Drug Market, by Type
7.1. Alpha-glucosidase Inhibitors
7.1.1. Overview
7.1.2. Market Sizing & Forecasting
7.2. Biguanides
7.2.1. Overview
7.2.2. Market Sizing & Forecasting
7.3. DPP-IV (Dipeptidyl Peptidase) Inhibitors
7.3.1. Overview
7.3.2. Market Sizing & Forecasting
7.4. GLP-1 (Glucagon-like Peptide) Agonists
7.4.1. Overview
7.4.2. Market Sizing & Forecasting
7.5. Insulin
7.5.1. Overview
7.5.2. Market Sizing & Forecasting
7.5.3. Intermediate-acting Insulin
7.5.4. Long-acting Analog
7.5.5. Premixed Insulin
7.5.6. Rapid-acting Analog
7.5.7. Short-acting Analog
7.6. Meglitinides
7.6.1. Overview
7.6.2. Market Sizing & Forecasting
7.7. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
7.7.1. Overview
7.7.2. Market Sizing & Forecasting
7.8. Sulphonylureas
7.8.1. Overview
7.8.2. Market Sizing & Forecasting
7.9. Thiazolidinedione
7.9.1. Overview
7.9.2. Market Sizing & Forecasting
8. Global Antidiabetic Drug Market, by Geography
8.1. Americas
8.1.1. Overview
8.1.2. Market Sizing & Forecasting
8.1.3. United States
8.2. Europe, Middle East & Africa
8.2.1. Overview
8.2.2. Market Sizing & Forecasting
8.2.3. United Kingdom
8.2.4. Germany
8.2.5. Saudi Arabia
8.3. Asia-Pacific
8.3.1. Overview
8.3.2. Market Sizing & Forecasting
8.3.3. China
8.3.4. Japan
8.3.5. India
9. 360iResearch FPNV Positioning Matrix
9.1. 360iResearch Scores
9.1.1. Forefront
9.1.2. Pathfinders
9.1.3. Niche
9.1.4. Vital
9.2. Business Strategy
9.3. Product Satisfaction
10. Competitive News Feed Analysis
11. Company Usability Profiles
11.1. AstraZeneca plc
11.1.1. Business Overview
11.1.2. Business Strategy
11.1.3. Business SWOT Analysis
11.2. Biocon Limited
11.2.1. Business Overview
11.2.2. Business Strategy
11.2.3. Business SWOT Analysis
11.3. Boehringer Ingelheim GmbH
11.3.1. Business Overview
11.3.2. Business Strategy
11.3.3. Business SWOT Analysis
11.4. Bristol-Myers Squibb Company
11.4.1. Business Overview
11.4.2. Business Strategy
11.4.3. Business SWOT Analysis
11.5. Eli Lilly and Company
11.5.1. Business Overview
11.5.2. Business Strategy
11.5.3. Business SWOT Analysis
11.6. Halozyme Therapeutics, Inc.
11.6.1. Business Overview
11.6.2. Business Strategy
11.6.3. Business SWOT Analysis
11.7. Johnson & Johnson
11.7.1. Business Overview
11.7.2. Business Strategy
11.7.3. Business SWOT Analysis
11.8. Merck KGaA
11.8.1. Business Overview
11.8.2. Business Strategy
11.8.3. Business SWOT Analysis
11.9. Novo Nordisk A/S
11.9.1. Business Overview
11.9.2. Business Strategy
11.9.3. Business SWOT Analysis
11.10. Oramed Pharmaceuticals Inc.
11.10.1. Business Overview
11.10.2. Business Strategy
11.10.3. Business SWOT Analysis
11.11. Pfizer Inc.
11.11.1. Business Overview
11.11.2. Business Strategy
11.11.3. Business SWOT Analysis
11.12. Takeda Pharmaceutical Company Ltd
11.12.1. Business Overview
11.12.2. Business Strategy
11.12.3. Business SWOT Analysis
11.13. Tonghua Dongbao Pharmaceutical Co., Ltd.
11.13.1. Business Overview
11.13.2. Business Strategy
11.13.3. Business SWOT Analysis
11.14. Wockhardt Limited
11.14.1. Business Overview
11.14.2. Business Strategy
11.14.3. Business SWOT Analysis
11.15. sanofi-aventis U.S. LLC
11.15.1. Business Overview
11.15.2. Business Strategy
11.15.3. Business SWOT Analysis
12. Appendix
12.1. Top Reports
12.2. Author Details

LIST OF TABLES (53 TABLES)

TABLE 1. GLOBAL ANTIDIABETIC DRUG MARKET RANKING, BY KEY PLAYER, 2017
TABLE 2. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 21. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 22. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 23. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 24. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 27. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 29. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 30. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 31. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 32. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 33. 360IRESEARCH SCORES FOR FOREFRONT IN ANTIDIABETIC DRUG MARKET
TABLE 34. 360IRESEARCH SCORES FOR PATHFINDERS IN ANTIDIABETIC DRUG MARKET
TABLE 35. 360IRESEARCH SCORES FOR NICHE IN ANTIDIABETIC DRUG MARKET
TABLE 36. 360IRESEARCH SCORES FOR VITAL IN ANTIDIABETIC DRUG MARKET
TABLE 37. 360IRESEARCH FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR ANTIDIABETIC DRUG MARKET
TABLE 38. 360IRESEARCH FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR ANTIDIABETIC DRUG MARKET
TABLE 39. COMPETITIVE NEWS FEED ANALYSIS FOR ASTRAZENECA PLC IN ANTIDIABETIC DRUG MARKET
TABLE 40. COMPETITIVE NEWS FEED ANALYSIS FOR BIOCON LIMITED IN ANTIDIABETIC DRUG MARKET
TABLE 41. COMPETITIVE NEWS FEED ANALYSIS FOR BOEHRINGER INGELHEIM GMBH IN ANTIDIABETIC DRUG MARKET
TABLE 42. COMPETITIVE NEWS FEED ANALYSIS FOR BRISTOL-MYERS SQUIBB COMPANY IN ANTIDIABETIC DRUG MARKET
TABLE 43. COMPETITIVE NEWS FEED ANALYSIS FOR ELI LILLY AND COMPANY IN ANTIDIABETIC DRUG MARKET
TABLE 44. COMPETITIVE NEWS FEED ANALYSIS FOR HALOZYME THERAPEUTICS, INC. IN ANTIDIABETIC DRUG MARKET
TABLE 45. COMPETITIVE NEWS FEED ANALYSIS FOR JOHNSON & JOHNSON IN ANTIDIABETIC DRUG MARKET
TABLE 46. COMPETITIVE NEWS FEED ANALYSIS FOR MERCK KGAA IN ANTIDIABETIC DRUG MARKET
TABLE 47. COMPETITIVE NEWS FEED ANALYSIS FOR NOVO NORDISK A/S IN ANTIDIABETIC DRUG MARKET
TABLE 48. COMPETITIVE NEWS FEED ANALYSIS FOR ORAMED PHARMACEUTICALS INC. IN ANTIDIABETIC DRUG MARKET
TABLE 49. COMPETITIVE NEWS FEED ANALYSIS FOR PFIZER INC. IN ANTIDIABETIC DRUG MARKET
TABLE 50. COMPETITIVE NEWS FEED ANALYSIS FOR TAKEDA PHARMACEUTICAL COMPANY LTD IN ANTIDIABETIC DRUG MARKET
TABLE 51. COMPETITIVE NEWS FEED ANALYSIS FOR TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. IN ANTIDIABETIC DRUG MARKET
TABLE 52. COMPETITIVE NEWS FEED ANALYSIS FOR WOCKHARDT LIMITED IN ANTIDIABETIC DRUG MARKET
TABLE 53. COMPETITIVE NEWS FEED ANALYSIS FOR SANOFI-AVENTIS U.S. LLC IN ANTIDIABETIC DRUG MARKET

LIST OF FIGURES (66 TABLES)

FIGURE 1. GLOBAL ANTIDIABETIC DRUG MARKET: YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH METHODOLOGY
FIGURE 3. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH INSTRUMENTS
FIGURE 4. GLOBAL ANTIDIABETIC DRUG MARKET: KEY SECONDARY INSTRUMENT SOURCES
FIGURE 5. GLOBAL ANTIDIABETIC DRUG MARKET: KEY POTENTIAL RESPONDENTS
FIGURE 6. GLOBAL ANTIDIABETIC DRUG MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT
FIGURE 7. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH APPROACHES
FIGURE 8. GLOBAL ANTIDIABETIC DRUG MARKET: KEY DATA TRIANGULATION
FIGURE 9. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH ASSUMPTIONS
FIGURE 10. ANTIDIABETIC DRUG MARKET: KEY MARKET CONNECTIVITY
FIGURE 11. GLOBAL ANTIDIABETIC DRUG MARKET SHARE, BY GEOGRAPHY, 2017 (%)
FIGURE 12. GLOBAL ANTIDIABETIC DRUG MARKET SHARE, BY DISEASE , 2017 (%)
FIGURE 13. GLOBAL ANTIDIABETIC DRUG MARKET SHARE, BY PATIENT, 2017 (%)
FIGURE 14. GLOBAL ANTIDIABETIC DRUG MARKET SHARE, BY TYPE, 2017 (%)
FIGURE 15. GLOBAL ANTIDIABETIC DRUG MARKET: KEY MARKET DYNAMICS
FIGURE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
FIGURE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 18. GLOBAL ANTIDIABETIC DRUG MARKET OPPORTUNITY ANALYSIS, BY GEOGRAPHY, 2024 (USD BILLION)
FIGURE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2017 (USD BILLION)
FIGURE 20. GLOBAL ANTIDIABETIC DRUG MARKET OPPORTUNITY ANALYSIS, BY DISEASE , 2024 (USD BILLION)
FIGURE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017 (USD BILLION)
FIGURE 22. GLOBAL ANTIDIABETIC DRUG MARKET OPPORTUNITY ANALYSIS, BY PATIENT, 2024 (USD BILLION)
FIGURE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017 (USD BILLION)
FIGURE 24. GLOBAL ANTIDIABETIC DRUG MARKET OPPORTUNITY ANALYSIS, BY TYPE, 2024 (USD BILLION)
FIGURE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 26. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 27. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 28. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 29. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 30. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 31. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 32. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 33. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 34. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 35. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 36. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 37. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 38. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 39. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 40. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 41. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 42. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 43. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 44. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 45. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 46. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 47. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 48. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 49. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 50. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 51. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 52. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 53. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 54. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, 2017 VS 2024 (USD BILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 56. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, 2017 VS 2024 (USD BILLION)
FIGURE 57. GERMANY ANTIDIABETIC DRUG MARKET SIZE, 2017 VS 2024 (USD BILLION)
FIGURE 58. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, 2017 VS 2024 (USD BILLION)
FIGURE 59. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 60. CHINA ANTIDIABETIC DRUG MARKET SIZE, 2017 VS 2024 (USD BILLION)
FIGURE 61. JAPAN ANTIDIABETIC DRUG MARKET SIZE, 2017 VS 2024 (USD BILLION)
FIGURE 62. INDIA ANTIDIABETIC DRUG MARKET SIZE, 2017 VS 2024 (USD BILLION)
FIGURE 63. 360IRESEARCH FPNV POSITIONING MATRIX FOR ANTIDIABETIC DRUG MARKET
FIGURE 64. COMPETITIVE NEWS FEED ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY NEWS TYPE
FIGURE 65. COMPETITIVE NEWS FEED ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY COMPANY
FIGURE 66. COMPETITIVE NEWS FEED ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY YEAR

“Changing lifestyle of people and irregular dietary habits
is one of the factors largely attributing to the growth of antidiabetic drug market globally”

The global antidiabetic drug market is expected to grow from USD 56.93 billion 2017 to USD 81.82 billion by the end of 2024, at a Compound Annual Growth Rate (CAGR) of 5.32%.

Market Segmentation & Coverage: The report on global antidiabetic drug market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the economies and geographies of the potential customer group can help to gain business acumen for better strategic decision making. Our market coverage across different industry verticals reveals the hidden truth about the strategies adopted by the players in different verticals and help the organization to decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.This research report categorizes the global antidiabetic drug market to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease
1. Diabetes Mellitus Type 1
2. Diabetes Mellitus Type 2

Based on Patient
1. Adult
2. Geriatric
3. Pediatric

Based on Type
1. Alpha-glucosidase Inhibitors
2. Biguanides
3. DPP-IV (Dipeptidyl Peptidase) Inhibitors
4. GLP-1 (Glucagon-like Peptide) Agonists
5. Insulin
6. Meglitinides
7. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
8. Sulphonylureas
9. Thiazolidinedione

Based on Geography
1. Americas (United States)
2. Europe, Middle East & Africa (United Kingdom, Germany, and Saudi Arabia)
3. Asia-Pacific (China, Japan, and India)

Company Usability Profiles:
The antidiabetic drug market research report provides the company usability profiles and analyze the business overview, business product offering, SWOT analysis, and business strategy of the following company:
1. AstraZeneca plc
2. Biocon Limited
3. Boehringer Ingelheim GmbH
4. Bristol-Myers Squibb Company
5. Eli Lilly and Company
6. Halozyme Therapeutics, Inc.
7. Johnson & Johnson
8. Merck KGaA
9. Novo Nordisk A/S
10. Oramed Pharmaceuticals Inc.
11. Pfizer Inc.
12. Takeda Pharmaceutical Company Ltd
13. Tonghua Dongbao Pharmaceutical Co., Ltd.
14. Wockhardt Limited
15. sanofi-aventis U.S. LLC

Research Methodology:
Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

Reasons to Buy:
1. To comprehensively understand of the antidiabetic drug market with respect to major influencing factor such as drivers, restraints, opportunities and challenges
2. To strategically analyze each vertical and geographic sub-segment in the antidiabetic drug market and its individual growth and its impact towards the growth of overall market
3. To position selected vendors in 360iResearch FPNV Positioning Matrix for the antidiabetic drug market to uncover a competitive landscape based on business strategy and product satisfaction




Summary:
Get latest Market Research Reports on Antidiabetic Drug. Industry analysis & Market Report on Antidiabetic Drug is a syndicated market report, published as The global antidiabetic drug market is expected to grow from USD 56.93 billion 2017 to USD 81.82 billion by the end of 2024, at a CAGR of 5.32%.. It is complete Research Study and Industry Analysis of Antidiabetic Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$2,999.00
$3,999.00
$4,999.00
2,013.83
2,685.33
3,356.83
2,759.68
3,679.88
4,600.08
363,298.86
484,438.86
605,578.86
198,873.89
265,187.29
331,500.69
Add To Cart Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report